Carcinoma escamoso de vulva. Hallazgos clínico patológicos. Vías de carciogénesis

Olga Gabriela Pérez; Paul Stiven Anaya; María Victoria Ferrea; Sofía Nascel; Marisol Choquevillca; Florencia García Kammerman; Viviana Catalano; Gisela Castro; Rita Mariel Correa; Gabriela Tachdjian; Roberto Ricardo Glorio; Sergio Gabriel Carbia

doi:10.47196/da.v30i3.2667

Authors

Olga Gabriela Pérez José María Penna General Acute Hospital (HGA), City of Buenos Aires, Argentina
Paul Stiven Anaya HGA Dr. Ignacio Pirovano, City of Buenos Aires, Argentina
María Victoria Ferrea HGA Dr. José María Penna, City of Buenos Aires, Argentina
Sofía Nascel HGA Dr. José María Penna, City of Buenos Aires, Argentina
Marisol Choquevillca HGA Dr. José María Penna, City of Buenos Aires, Argentina
Florencia García Kammerman José de San Martín Clinical Hospital, City of Buenos Aires, Argentina
Viviana Catalano HGA Juan Fernández, City of Buenos Aires, Argentina
Gisela Castro HGA Dr. José María Penna, City of Buenos Aires, Argentina
Rita Mariel Correa National Institute of Infectious Diseases (ANLIS), Dr. Malbrán, City of Buenos Aires, Argentina
Gabriela Tachdjian HGA Dr. José María Penna, City of Buenos Aires, Argentina
Roberto Ricardo Glorio Dr. José María Penna, City of Buenos Aires, Argentina
Sergio Gabriel Carbia HGA Dr. José María Penna, City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v30i3.2667

Keywords:

vulvar squamous cell carcinoma, immunohistochemistry, papillomavirus, lichen sclerosus, p16, p53

Abstract

Vulvar squamous cell carcinoma (VSC) can develop associated or not with human papillomavirus (HPV) infection. The objective of the work was to evaluate the agreement between clinical features, histology, immunophenotype, treatment and evolution of 17 cases studied in the Pathology, Gynecology and Dermatology services of the Peña Hospital in Buenos Aires. The immunohistochemical study showed a pattern of p16 +/p53 wild type (wt) (8/17), p16-/p53 mutated (7/17) and p16-/p53 wt (2/17). The stages (E) in the p16+ group were: E-I (4 patients [pat.]), E-II (1 pat.), E-III (2 pat.) and E-IV (1 pat.); in the p16- group were: E-II (2 pat.), E-III (6 pat.) and E-IV (1 pat.). The subdivision of CEVs into clinical subgroups according to the expression of p16 and p53 allow us to understand evolution. It is recommended to implement this study in the routine pathological diagnosis of CEVs.

Author Biographies

Olga Gabriela Pérez, José María Penna General Acute Hospital (HGA), City of Buenos Aires, Argentina

Specialist in Dermatology and Pathology, UBA, Medical Staff, Pathological Anatomy Service

Paul Stiven Anaya, HGA Dr. Ignacio Pirovano, City of Buenos Aires, Argentina

Resident Physician, Pathological Anatomy Service

María Victoria Ferrea, HGA Dr. José María Penna, City of Buenos Aires, Argentina

Head of Residents, Dermatology Service

Sofía Nascel, HGA Dr. José María Penna, City of Buenos Aires, Argentina

Physician, Dermatology Service

Marisol Choquevillca, HGA Dr. José María Penna, City of Buenos Aires, Argentina

Resident Physician, Pathological Anatomy Service

Florencia García Kammerman, José de San Martín Clinical Hospital, City of Buenos Aires, Argentina

Medical Specialist in Pathological Anatomy and Cytology, Medical Staff, Division of Gynecological Pathology, Lower Genital Tract Section

Viviana Catalano, HGA Juan Fernández, City of Buenos Aires, Argentina

Preparatory Technician in Histology

Gisela Castro, HGA Dr. José María Penna, City of Buenos Aires, Argentina

Staff Physician, Gynecology Service, Specialist in Lower Genital Tract Pathology

Rita Mariel Correa, National Institute of Infectious Diseases (ANLIS), Dr. Malbrán, City of Buenos Aires, Argentina

Biochemistry, Oncogenic Virus Service, National and Regional Papillomavirus Reference Laboratory, PAHO/WHO

Gabriela Tachdjian, HGA Dr. José María Penna, City of Buenos Aires, Argentina

Medical Specialist in Pathological Anatomy and Cytology, Head of the Pathological Anatomy Service

Roberto Ricardo Glorio, Dr. José María Penna, City of Buenos Aires, Argentina

Physician, Associate Professor, UBA, Doctor of Medicine, UBA, HGA

Sergio Gabriel Carbia, HGA Dr. José María Penna, City of Buenos Aires, Argentina

Physician, Head of the Dermatology Service

References

I. Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. Int J Gynaecol Obstet. 2021;155:7-18.

II. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics 2023. CA Cancer J Clin. 2023;73:17-48.

III. Sistema de Vigilancia Epidemiológica y Reporte del Cáncer. Boletín de mortalidad por cáncer en Argentina. SIVER-Ca con base de datos de la DEIS. Ministerio de Salud. Consultado: septiembre 2023.

IV. Wohlmuth C, Wohlmuth-Wieser I. Vulvar malignancies: an interdisciplinary perspective. J Dtsch Dermatol Ges. 2019;17:1257-1276.

V. Tan A, Bieber AK, Stein JA, Pomeranz MK. Diagnosis and management of vulvar cancer. A review. J Am Acad Dermatol. 2019;81:1387-1396.

VI. Asociación Argentina de Ginecología Oncológica. Guías clínicas para el diagnóstico, tratamiento y seguimiento del cáncer genital femenino. 3º Edición. Editorial Ascune 2016. Capítulo: Cáncer de vulva:129-148.

VII. Oonk MHM, F, Baldwin P, Mahner S, et ál. European society of gynaecological oncology guidelines for the management of patients with vulvar cancer update 2023. Int J Gynecol Cancer. 2023;33:1023-1043.

VIII. Höhn AK, Brambs CE, Hiller GGR, May D, et ál. 2020 WHO Classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021;81:1145-1153.

IX. Falcón MF, Paradeda ME, Kamermann FG, Maldonado V, et ál. Immunohistochemistry of p16 and p53 in vulvar cancer. Medicina (B Aires). 2020;80:127-133.

X. Boyle W, Ganesan R. Vulval carcinomas. An update. Diagnostic Histopathology. 2021;27:472-477.

XI. Barlow EL, Lambie N, Donoghoe MW, Naing Z, et ál. The clinical relevance of p16 and p53 status in patients with squamous cell carcinoma of the vulva. J Oncol. 2020;3739075.

XII. Woelber L, Prieske K, Eulenburg C, Oliveira-Ferrer L, et ál. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. Am J Obstet Gynecol. 2021;224:595.e1-595.e11.

XIII. Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, et ál. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol. 2020;159: 649-656.

XIV. Tessier-Cloutier B, Kortekaas KE, Thompson E, Chen J, et ál. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. 2020;33:1595- 1605.

XV. Van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, et ál. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779-87.

XVI. Bermejo A, Rodríguez EA, Leiro V, Mestroni M, et ál. Consenso sobre virus papiloma humano (HPV) y herpes simplex virus (HSV) 2016. Sociedad Argentina de Dermatología. Disponible en: www.sad.org.ar/wpcontent/uploads/2016/04/Consenso-HPV-y-HSV-2016 pdf. Consultado marzo de 2024.

XVII. Osuna-Marco M, López- Barahona M, López-Ibor B, Tejera Á. Ten reasons why people with down syndrome are protected from the development of most solid tumors. A review. Front Genet. 2021;12:1-12.

XVIII. De Luca D, Papara C, Vorobyev A, Staiger H, et ál. Lichen sclerosus: the 2023 update. Front Med. 2023;10:1-20.

XIX. Day T, Selim A, Allbritton J, Scurry J. Nonsclerotic lichen sclerosus: definition of a concept and pathologic description. J Low Genit Tract Dis. 2023;27:358-364.

XX. Saunders H, Buchanan JAG, Cooper S, Hollowood K, et ál. The period prevalence of oral lichen planus in a cohort of patients with vulvar lichen sclerosus. JEADV 2010;24:18-21.

Squamous cell carcinoma of the vulva. Clinicopathological findings. Pathways of carcinogenesis